Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 9, Issue 5 (2020)

Molecular diagnosis of bovine papillomatosis and a successful management with autogenous vaccine

Author(s):
D Rani Prameela and P Veena
Abstract:
Bovine papillomatosis is caused by papilloma viruses. Thirty six cases of bovine papillomatosis were brought to the clinics, Department of Surgery and Radiology, C.V.Sc, SVVU, Tirupati. On clinical observations of the wart lesions, it was diagnosed as bovine papillomas. Wart samples were collected aseptically and processed for Molecular diagnosis. All the thirty six wart samples were subjected for for homogenization under sterile conditions with tissue lyser. All the thirty six wart samples were subjected for homogenization under sterile conditions with tissue lyser. DNA was extracted from tissue homogenates and subjected for molecular diagnosis with PCR targeting L1 gene. Out of 36 samples, five (5) were positive for BPV Type-1, eight for positive for BPV type -2 and eleven were positive for both BPV-1 & BPV-2 and remaining twelve samples were positive for BPV Type-5 with species specific primers. Later as a therapeutic measure, an autogenous vaccine was prepared. The wart samples collected aseptically from all the affected animals and adjuvanted with aluminium hydroxide. After sterility checkup the vaccine was administered for affected animals subcutaneously to cows @10ml and heifer calves@5ml on 0th day and then subsequently 10 days interval for 5 doses. The regression of the warts was started by three weeks of post vaccination and complete regression was appreciated by 6th week. The study represents the presence of the bovine papilloma virus type 5 on molecular diagnosis and successful management of bovine papilloma with bovine specific autogenous vaccine.
Pages: 265-269  |  538 Views  114 Downloads


The Pharma Innovation Journal
How to cite this article:
D Rani Prameela, P Veena. Molecular diagnosis of bovine papillomatosis and a successful management with autogenous vaccine. Pharma Innovation 2020;9(5):265-269.

Call for book chapter